Qube Research & Technologies LTD Lineage Cell Therapeutics, Inc. Transaction History

Qube Research & Technologies LTD

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.89 - $1.47 $49,095 - $81,089	55,163 Added 420.35%	68,286 $68,000
Q1 2024 May 14, 2024	BUY	$0.86 - $1.48 $11,285 - $19,422	13,123 New	13,123 $19,000
Q1 2023 May 15, 2023	BUY	$1.2 - $1.53 $101,253 - $129,098	84,378 Added 61.34%	221,946 $332,000
Q4 2022 Feb 14, 2023	BUY	$1.02 - $1.5 $34,930 - $51,369	34,246 Added 33.14%	137,568 $160,000
Q3 2022 Nov 14, 2022	BUY	$1.13 - $1.77 $15,099 - $23,650	13,362 Added 14.85%	103,322 $117,000
Q2 2022 Aug 15, 2022	BUY	$1.12 - $1.61 $100,755 - $144,835	89,960 New	89,960 $142,000
Q2 2021 Aug 13, 2021	SELL	$2.17 - $3.0 $415,518 - $574,449	-191,483 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$1.77 - $3.1 $6,228 - $10,908	3,519 Added 1.87%	191,483 $450,000
Q4 2020 Feb 16, 2021	BUY	$0.95 - $1.83 $86,697 - $167,005	91,260 Added 94.37%	187,964 $331,000
Q3 2020 Nov 12, 2020	SELL	$0.75 - $1.09 $28,825 - $41,893	-38,434 Reduced 28.44%	96,704 $91,000
Q2 2020 Aug 14, 2020	BUY	$0.71 - $1.18 $95,947 - $159,462	135,138 New	135,138 $118,000

120

94.2M

63.8K

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $84.9M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.